These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
584 related articles for article (PubMed ID: 25476752)
1. Nucleo-cytoplasmic transport as a therapeutic target of cancer. Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Turner JG; Dawson J; Cubitt CL; Baz R; Sullivan DM Semin Cancer Biol; 2014 Aug; 27():62-73. PubMed ID: 24631834 [TBL] [Abstract][Full Text] [Related]
3. Nuclear export of proteins and drug resistance in cancer. Turner JG; Dawson J; Sullivan DM Biochem Pharmacol; 2012 Apr; 83(8):1021-32. PubMed ID: 22209898 [TBL] [Abstract][Full Text] [Related]
4. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315 [TBL] [Abstract][Full Text] [Related]
5. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma. Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088 [TBL] [Abstract][Full Text] [Related]
6. The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials. Lai C; Xu L; Dai S Clin Transl Med; 2024 May; 14(5):e1684. PubMed ID: 38783482 [TBL] [Abstract][Full Text] [Related]
7. Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer. Sexton R; Mahdi Z; Chaudhury R; Beydoun R; Aboukameel A; Khan HY; Baloglu E; Senapedis W; Landesman Y; Tesfaye A; Kim S; Philip PA; Azmi AS Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569391 [TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791 [TBL] [Abstract][Full Text] [Related]
9. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds. Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943 [TBL] [Abstract][Full Text] [Related]
10. Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents. Parikh K; Cang S; Sekhri A; Liu D J Hematol Oncol; 2014 Oct; 7():78. PubMed ID: 25316614 [TBL] [Abstract][Full Text] [Related]
11. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor. Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935 [TBL] [Abstract][Full Text] [Related]
13. SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents. Gerecitano J J Hematol Oncol; 2014 Oct; 7():67. PubMed ID: 25281264 [TBL] [Abstract][Full Text] [Related]
14. Understanding XPO1 target networks using systems biology and mathematical modeling. Muqbil I; Kauffman M; Shacham S; Mohammad RM; Azmi AS Curr Pharm Des; 2014; 20(1):56-65. PubMed ID: 23530499 [TBL] [Abstract][Full Text] [Related]
15. Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines. Breit MN; Kisseberth WC; Bear MD; Landesman Y; Kashyap T; McCauley D; Kauffman MG; Shacham S; London CA BMC Vet Res; 2014 Jul; 10():160. PubMed ID: 25022346 [TBL] [Abstract][Full Text] [Related]
16. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336 [TBL] [Abstract][Full Text] [Related]
17. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds. Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568 [TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556 [TBL] [Abstract][Full Text] [Related]